199 related articles for article (PubMed ID: 12649387)
21. Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: a microdialysis study.
Shearman E; Rossi S; Szasz B; Juranyi Z; Fallon S; Pomara N; Sershen H; Lajtha A
Brain Res Bull; 2006 Mar; 69(2):204-13. PubMed ID: 16533671
[TBL] [Abstract][Full Text] [Related]
22. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
[TBL] [Abstract][Full Text] [Related]
23. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
Brocco M; Dekeyne A; Papp M; Millan MJ
Behav Pharmacol; 2006 Nov; 17(7):559-72. PubMed ID: 17021388
[TBL] [Abstract][Full Text] [Related]
24. Partial to complete antagonism by putative antagonists at the wild-type alpha(2C)-adrenoceptor based on kinetic analyses of agonist:antagonist interactions.
Pauwels PJ; Colpaert FC
Br J Pharmacol; 2000 Dec; 131(7):1385-90. PubMed ID: 11090111
[TBL] [Abstract][Full Text] [Related]
25. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
[TBL] [Abstract][Full Text] [Related]
26. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.
Millan MJ; Loiseau F; Dekeyne A; Gobert A; Flik G; Cremers TI; Rivet JM; Sicard D; Billiras R; Brocco M
J Pharmacol Exp Ther; 2008 Mar; 324(3):1212-26. PubMed ID: 18096759
[TBL] [Abstract][Full Text] [Related]
27. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
Millan MJ; Maiofiss L; Cussac D; Audinot V; Boutin JA; Newman-Tancredi A
J Pharmacol Exp Ther; 2002 Nov; 303(2):791-804. PubMed ID: 12388666
[TBL] [Abstract][Full Text] [Related]
28. Enhanced stability of wild-type and constitutively active alpha(2A)-adrenoceptors by ligands with agonist, silent and inverse agonist properties.
Pauwels PJ; Tardif S
Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):134-41. PubMed ID: 12122500
[TBL] [Abstract][Full Text] [Related]
29. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
[TBL] [Abstract][Full Text] [Related]
30. Serotonergic modulation of acetylcholine release from cortex of freely moving rats.
Giovannini MG; Ceccarelli I; Molinari B; Cecchi M; Goldfarb J; Blandina P
J Pharmacol Exp Ther; 1998 Jun; 285(3):1219-25. PubMed ID: 9618425
[TBL] [Abstract][Full Text] [Related]
31. Facilitation of constitutive alpha(2A)-adrenoceptor activity by both single amino acid mutation (Thr(373)Lys) and g(alphao) protein coexpression: evidence for inverse agonism.
Pauwels PJ; Tardif S; Wurch T; Colpaert FC
J Pharmacol Exp Ther; 2000 Feb; 292(2):654-63. PubMed ID: 10640303
[TBL] [Abstract][Full Text] [Related]
32. Modulation of Delta(9)-THC-induced increase of cortical and hippocampal acetylcholine release by micro opioid and D(1) dopamine receptors.
Pisanu A; Acquas E; Fenu S; Di Chiara G
Neuropharmacology; 2006 May; 50(6):661-70. PubMed ID: 16427098
[TBL] [Abstract][Full Text] [Related]
33. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization.
Dekeyne A; Brocco M; Loiseau F; Gobert A; Rivet JM; Di Cara B; Cremers TI; Flik G; Fone KC; Watson DJ; Papp M; Sharp T; Serres F; Cespuglio R; Olivier B; Chan JS; Lavielle G; Millan MJ
J Pharmacol Exp Ther; 2012 Mar; 340(3):765-80. PubMed ID: 22178753
[TBL] [Abstract][Full Text] [Related]
34. Alpha2A adrenergic receptor activation inhibits epileptiform activity in the rat hippocampal CA3 region.
Jurgens CW; Hammad HM; Lichter JA; Boese SJ; Nelson BW; Goldenstein BL; Davis KL; Xu K; Hillman KL; Porter JE; Doze VA
Mol Pharmacol; 2007 Jun; 71(6):1572-81. PubMed ID: 17341653
[TBL] [Abstract][Full Text] [Related]
35. Effects of divalproex and atypical antipsychotic drugs on dopamine and acetylcholine efflux in rat hippocampus and prefrontal cortex.
Huang M; Li Z; Ichikawa J; Dai J; Meltzer HY
Brain Res; 2006 Jul; 1099(1):44-55. PubMed ID: 16824491
[TBL] [Abstract][Full Text] [Related]
36. Caffeine enhances acetylcholine release in the hippocampus in vivo by a selective interaction with adenosine A1 receptors.
Carter AJ; O'Connor WT; Carter MJ; Ungerstedt U
J Pharmacol Exp Ther; 1995 May; 273(2):637-42. PubMed ID: 7752065
[TBL] [Abstract][Full Text] [Related]
37. Hippocampal noradrenaline release in awake, freely moving rats is regulated by alpha-2 adrenoceptors but not by adenosine receptors.
Carter AJ
J Pharmacol Exp Ther; 1997 May; 281(2):648-54. PubMed ID: 9152369
[TBL] [Abstract][Full Text] [Related]
38. Microdialysis measures of functional increases in ACh release in the hippocampus with and without inclusion of acetylcholinesterase inhibitors in the perfusate.
Chang Q; Savage LM; Gold PE
J Neurochem; 2006 May; 97(3):697-706. PubMed ID: 16579834
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological characterization and autoradiographic distribution of alpha2-adrenoceptor antagonist [3H]RX 821002 binding sites in the chicken brain.
Díez-Alarcia R; Pilar-Cuéllar F; Paniagua MA; Meana JJ; Fernández-López A
Neuroscience; 2006 Aug; 141(1):357-69. PubMed ID: 16697114
[TBL] [Abstract][Full Text] [Related]
40. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice.
Ralph RJ; Caine SB
J Pharmacol Exp Ther; 2005 Feb; 312(2):733-41. PubMed ID: 15494551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
